Search

Your search keyword '"Gradellini F"' showing total 2 results
Start Over Author "Gradellini F" Topic covid-19
2 results on '"Gradellini F"'

1. Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy.

Author

Salvarani C, Mancuso P, Gradellini F, Viani N, Pandolfi P, Reta M, Carrozzi G, Sandri G, Bajocchi G, Galli E, Muratore F, Boiardi L, Pipitone N, Cassone G, Croci S, Marata AM, Costantini M, and Giorgi Rossi P

Subjects
Adult, Aged, Aged, 80 and over, Antimalarials therapeutic use, Arthritis, Juvenile drug therapy, Arthritis, Rheumatoid drug therapy, COVID-19 prevention & control, Disease Susceptibility, Female, Humans, Italy epidemiology, Lupus Erythematosus, Discoid drug therapy, Lupus Erythematosus, Systemic drug therapy, Male, Middle Aged, Odds Ratio, SARS-CoV-2, Antirheumatic Agents therapeutic use, Autoimmune Diseases drug therapy, COVID-19 epidemiology, Chloroquine therapeutic use, Hydroxychloroquine therapeutic use
Abstract

Objective: To evaluate the susceptibility to coronavirus disease 2019 (COVID-19) in patients with autoimmune conditions treated with antimalarials in a population-based study., Methods: All residents treated with chloroquine (CQ)/hydroxychloroquine (HCQ) from July through December 2019 and living in 3 provinces of Regione Emilia-Romagna were identified by drug prescription registries and matched with the registry containing all residents living in the same areas who have had swabs and tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated., Results: A total of 4,408 patients were identified. The prevalence of patients receiving antimalarials was 0.85 per 1,000 men and 3.3 per 1,000 women. The cumulative incidence of testing during the study period was 2.7% in the general population and 3.8% among those receiving CQ or HCQ, while the cumulative incidence of testing positive was 0.55% in the general population and 0.70% among those receiving CQ/HCQ. Multivariate models showed that those receiving CQ/HCQ had a slightly higher probability of being tested compared to the general population (OR 1.09 [95% CI 0.94-1.28]), the same probability of being diagnosed as having COVID-19 (OR 0.94 [95% CI 0.66-1.34]), and a slightly lower probability of being positive once tested (OR 0.83 [95% CI 0.56-1.23]). None of the differences were significant., Conclusion: Our findings do not support the use of antimalarials as a prophylactic treatment of COVID-19., (© 2020, American College of Rheumatology.)

Published
2021
Full Text
View/download PDF

2. Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study

Author

Salvarani, C., Bajocchi, G., Mancuso, P., Galli, E., Muratore, F., Boiardi, L., Catanoso, M., Pipitone, N., Cassone, G., Girolimetto, N., Croci, S., Cimino, L., Gradellini, F., Beltrami, M., Di Lernia, V., Dolci, G., Massari, M., Marata, A. M., Costantini, M., and Giorgi Rossi, P.

Subjects
Male, 0301 basic medicine, Severity of Illness Index, 0302 clinical medicine, Piperidines, Risk Factors, Epidemiology, Immunology and Allergy, media_common, Sulfonamides, education.field_of_study, Middle Aged, Hospitalization, Antirheumatic Agents, Italy, Female, Ustekinumab, Disease Susceptibility, Coronavirus Infections, autoimmune diseases, biological therapy, epidemiology, Abatacept, Adult, Aged, Antibodies, Monoclonal, Humanized, Azetidines, Betacoronavirus, Humans, Interleukin 1 Receptor Antagonist Protein, Janus Kinase Inhibitors, Logistic Models, Pandemics, Pneumonia, Viral, Proportional Hazards Models, Pyrimidines, Pyrroles, Rheumatic Diseases, Tumor Necrosis Factor Inhibitors, medicine.drug, Drug, medicine.medical_specialty, media_common.quotation_subject, Immunology, Population, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, Rheumatology, Internal medicine, Severity of illness, medicine, education, 030203 arthritis & rheumatology, SARS-CoV-2, business.industry, Proportional hazards model, COVID-19, 030104 developmental biology, Purines, Pyrazoles, business
Abstract

Patients with autoimmune conditions treated with biological agents have an increased risk of severe infections.1 2 Very few studies have evaluated the susceptibility and severity of coronavirus disease 2019 (COVID-19) in patients treated with biological disease-modifying antirheumatic drugs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs).3 4 Some of these studies suggest a protective role of these drugs for COVID-19; however, they consist of small series, and the results are unclear. Therefore, we decided to evaluate in a population-based study the risk of COVID-19 infection and its severity in the patients treated with bDMARDs or tsDMARDs in a geographic area (Emilia Romagna) at high diffusion of COVID-19. We identified 1195 patients treated with the bDMARDs or tsDMARDs listed in table 1 in Reggio Emilia area on 31 December 2019. Biological agents were classified according to the mechanism of action. The patients were registered in the database of the Hospital Pharmaceutical Service of the Reggio Emilia area, which delivers the drug directly to the patients. The database is updated every 3 months. All residents …

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results